Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

Topline Summary and Update Financial Overview As of their Q1 filing, CLRB held $41.4 million in current assets, made up mostly of $40.0 million in cash and equivalents. Their operating expenses, or cash burn, for the quarter reached $12.0 million. After recognizing an addition $9.9 million in losses due to valuation of their warrants, the net loss for the quarter was $21.6 million. Cellectar Biosciences, Inc. (NASDAQ:CLRB) is a radiopharmaceutical-focused developmental biotech training their sites on a firs ...